Journal of Shanghai Jiao Tong University (Medical Science) >
Review of the factors influencing bone metabolism in schizophrenia
Online published: 2021-08-03
Supported by
Shanghai Clinical Research Center for Mental Health(19MC1911100);Project of Shanghai Municipal Commission of Health and Family Planning(201740089)
The patients with schizophrenia experience a higher rate of low bone mineral density, osteoporosis and fractures than the general population, which affects not only their quality of life but also their long-term outcomes. Previous studies have shown that there are many factors affecting individual bone metabolism, including drugs, gender, age, hypogonadism, lifestyle, etc. Combined with clinical research, this article summarizes three aspects, i.e.,the disease itself, the use of antipsychotics and the unhealthy lifestyle. This review aims to discuss the influencing factors of bone metabolism in the patients with schizophrenia, and then expound briefly on the diagnosis and intervention measures of osteoporosis, which may provide a reference for clinical prevention and intervention of osteoporosis in the patients with schizophrenia.
Key words： schizophrenia; osteoporosis; bone metabolism; antipsychotics
Hong-yan XUAN , Li-hua WANG , Hua-fang LI . Review of the factors influencing bone metabolism in schizophrenia[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2021 , 41(7) : 972 -976 . DOI: 10.3969/j.issn.1674-8115.2021.07.021
| 1 | Stubbs B, De Hert M, Sepehry AA, et al. A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia[J]. Acta Psychiatr Scand, 2014, 130(6): 470-486. |
| 2 | Cui JY, Liu HQ, Shao J, et al. Prevalence, risk factors and clinical characteristics of osteoporosis in Chinese inpatients with schizophrenia[J]. Schizophr Res, 2018, 195: 488-494. |
| 3 | Tseng PT, Chen YW, Yeh PY, et al. Bone mineral density in schizophrenia: an update of current meta-analysis and literature review under guideline of PRISMA[J]. Medicine (Baltimore), 2015, 94(47): e1967. |
| 4 | Partti K, Heli?vaara M, Impivaara O, et al. Skeletal status in psychotic disorders: a population-based study[J]. Psychosom Med, 2010, 72(9): 933-940. |
| 5 | 冒雷明, 周春英, 胡亚兰, 等. 首发精神分裂症患者骨密度检测及影响因素分析[J]. 临床心身疾病杂志, 2017, 23(6): 168-170. |
| 6 | Mayne PE, Burne THJ. Vitamin D in synaptic plasticity, cognitive function, and neuropsychiatric illness[J]. Trends Neurosci, 2019, 42(4): 293-306. |
| 7 | Berg AO, J?rgensen KN, Nerhus M, et al. Vitamin D levels, brain volume, and genetic architecture in patients with psychosis[J]. PLoS One, 2018, 13(8): e0200250. |
| 8 | Allott K, McGorry PD, Yuen HP, et al. The vitamins in psychosis study: a randomized, double-blind, placebo-controlled trial of the effects of vitamins B12, B6, and folic acid on symptoms and neurocognition in first-episode psychosis[J]. Biol Psychiatry, 2019, 86(1): 35-44. |
| 9 | Hubbard DB, Miller BJ. Meta-analysis of blood cortisol levels in individuals with first-episode psychosis[J]. Psychoneuroendocrinology, 2019, 104: 269-275. |
| 10 | Gyllenberg D, Sourander A, Surcel HM, et al. Hypothyroxinemia during gestation and offspring schizophrenia in a national birth cohort[J]. Biol Psychiatry, 2016, 79(12): 962-970. |
| 11 | Ko?ovská E, Gaughran F, Krivoy A, et al. Vitamin-D deficiency as a potential environmental risk factor in multiple sclerosis, schizophrenia, and autism[J]. Front Psychiatry, 2017, 8: 47. |
| 12 | van der Leeuw C, de Witte LD, Stellinga A, et al. Vitamin D concentration and psychotic disorder: associations with disease status, clinical variables and urbanicity[J]. Psychol Med, 2020, 50(10): 1680-1686. |
| 13 | Valipour G, Saneei P, Esmaillzadeh A. Serum vitamin D levels in relation to schizophrenia: a systematic review and meta-analysis of observational studies[J]. J Clin Endocrinol Metab, 2014, 99(10): 3863-3872. |
| 14 | Taylor AE, Burgess S, Ware JJ, et al. Investigating causality in the association between 25(OH)D and schizophrenia[J]. Sci Rep, 2016, 6: 26496. |
| 15 | Crews M, Lally J, Gardner-Sood P, et al. Vitamin D deficiency in first episode psychosis: a case-control study[J]. Schizophr Res, 2013, 150(2/3): 533-537. |
| 16 | Lally J, Ajnakina O, Singh N, et al. Vitamin D and clinical symptoms in First Episode Psychosis (FEP): a prospective cohort study[J]. Schizophr Res, 2019, 204: 381-388. |
| 17 | Muscogiuri G, Altieri B, de Angelis C, et al. Shedding new light on female fertility: the role of vitamin D[J]. Rev Endocr Metab Disord, 2017, 18(3): 273-283. |
| 18 | Levine J, Stahl Z, Sela BA, et al. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia[J]. Biol Psychiatry, 2006, 60(3): 265-269. |
| 19 | Petronijevi? ND, Radonji? NV, Ivkovi? MD, et al. Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2008, 32(8): 1921-1926. |
| 20 | Weber DR, Coughlin C, Brodsky JL, et al. Low bone mineral density is a common finding in patients with homocystinuria[J]. Mol Genet Metab, 2016, 117(3): 351-354. |
| 21 | Cherian K, Schatzberg AF, Keller J. HPA axis in psychotic major depression and schizophrenia spectrum disorders: cortisol, clinical symptomatology, and cognition[J]. Schizophr Res, 2019, 213: 72-79. |
| 22 | Girshkin L, Matheson SL, Shepherd AM, et al. Morning cortisol levels in schizophrenia and bipolar disorder: a meta-analysis[J]. Psychoneuroen-docrinology, 2014, 49: 187-206. |
| 23 | Hardy RS, Zhou H, Seibel MJ, et al. Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy[J]. Endocr Rev, 2018, 39(5): 519-548. |
| 24 | Noda M. Possible role of glial cells in the relationship between thyroid dysfunction and mental disorders[J]. Front Cell Neurosci, 2015, 9: 194. |
| 25 | Sharif K, Tiosano S, Watad A, et al. The link between schizophrenia and hypothyroidism: a population-based study[J]. Immunol Res, 2018, 66(6): 663-667. |
| 26 | Williams GR, Bassett JHD. Thyroid diseases and bone health[J]. J Endocrinol Invest, 2018, 41(1): 99-109. |
| 27 | Nikoli? T, Petronijevi? M, Sopta J, et al. Haloperidol affects bones while clozapine alters metabolic parameters-sex specific effects in rats perinatally treated with phencyclidine[J]. BMC Pharmacol Toxicol, 2017, 18(1): 65. |
| 28 | Zhang BB, Deng L, Wu HS, et al. Relationship between long-term use of a typical antipsychotic medication by Chinese schizophrenia patients and the bone turnover markers serum osteocalcin and β-CrossLaps[J]. Schizophr Res, 2016, 176(2/3): 259-263. |
| 29 | Bolton JM, Morin SN, Majumdar SR, et al. Association of mental disorders and related medication use with risk for major osteoporotic fractures[J]. JAMA Psychiatry, 2017, 74(6): 641-648. |
| 30 | Inder WJ, Castle D. Antipsychotic-induced hyperprolactinaemia[J]. Aust N Z J Psychiatry, 2011, 45(10): 830-837. |
| 31 | Bernard V, Young J, Binart N. Prolactin-a pleiotropic factor in health and disease[J]. Nat Rev Endocrinol, 2019, 15(6): 356-365. |
| 32 | Liang MN, Zhang BB, Deng L, et al. Effects of olanzapine on bone mineral density, glucose, and lipid metabolism in schizophrenia patients[J]. Int J Endocrinol, 2019, 2019: 1312804. |
| 33 | Gomez L, Stubbs B, Shirazi A, et al. Lower bone mineral density at the hip and lumbar spine in people with psychosis versus controls: a comprehensive review and skeletal site-specific meta-analysis[J]. Curr Osteoporos Rep, 2016, 14(6): 249-259. |
| 34 | 李艳歌, 于文娟, 沈一峰, 等. 抗精神病药治疗精神分裂症导致催乳素水平差异的机制[J]. 上海交通大学学报(医学版), 2018, 38(7): 797-800. |
| 35 | Wang MX, Hou RH, Jian J, et al. Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study[J]. Hum Psychopharmacol, 2014, 29(2): 183-189. |
| 36 | Meaney AM, O'Keane V. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables[J]. Schizophr Res, 2007, 93(1-3): 136-143. |
| 37 | Lodhi RJ, Masand S, Malik A, et al. Changes in biomarkers of bone turnover in an aripiprazole add-on or switching study[J]. Schizophr Res, 2016, 170(2/3): 245-251. |
| 38 | Abraham G, Paing WW, Kaminski J, et al. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study[J]. Am J Psychiatry, 2003, 160(9): 1618-1620. |
| 39 | van der Leeuw C, Peeters S, Domen P, et al. Bone mineral density as a marker of cumulative estrogen exposure in psychotic disorder: a 3 year follow-up study[J]. PLoS One, 2015, 10(8): e0136320. |
| 40 | Clapham E, Bodén R, Reutfors J, et al. Exposure to risperidone versus other antipsychotics and risk of osteoporosis-related fractures: a population-based study[J]. Acta Psychiatr Scand, 2020, 141(1): 74-83. |
| 41 | Park YM, Lee SH, Lee BH, et al. Prolactin and macroprolactin levels in psychiatric patients receiving atypical antipsychotics: a preliminary study[J]. Psychiatry Res, 2016, 239: 184-189. |
| 42 | Kim HY, Choe JW, Kim HK, et al. Negative association between metabolic syndrome and bone mineral density in Koreans, especially in men[J]. Calcif Tissue Int, 2010, 86(5): 350-358. |
| 43 | Lin CH, Lin CY, Wang HS, et al. Long-term use of clozapine is protective for bone density in patients with schizophrenia[J]. Sci Rep, 2019, 9(1): 3895. |
| 44 | Qiu J, Gong HX, Wang BX, et al. The use of clozapine is protective for low bone mineral density induced by prolactin-raising antipsychotics in inpatients with schizophrenia[J]. Arch Osteoporos, 2020, 15(1): 98. |
| 45 | Faulkner G, Cohn T, Remington G. Validation of a physical activity assessment tool for individuals with schizophrenia[J]. Schizophr Res, 2006, 82(2/3): 225-231. |
| 46 | Mallet J, Le Strat Y, Schürhoff F, et al. Cigarette smoking and schizophrenia: a specific clinical and therapeutic profile? Results from the FACE-Schizophrenia cohort[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2017, 79(Pt B): 332-339. |
| 47 | Volkow ND. Substance use disorders in schizophrenia: clinical implications of comorbidity[J]. Schizophr Bull, 2009, 35(3): 469-472. |
| 48 | Roick C, Fritz-Wieacker A, Matschinger H, et al. Health habits of patients with schizophrenia[J]. Soc Psychiatry Psychiatr Epidemiol, 2007, 42(4): 268-276. |
| 49 | 张智海, 刘忠厚, 李娜, 等. 中国人骨质疏松症诊断标准专家共识(第三稿·2014版)[J]. 中国骨质疏松杂志, 2014, 20(9): 1007-1010. |
| 50 | 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 原发性骨质疏松症基层诊疗指南(2019年)[J]. 中华全科医师杂志, 2020, 19(4): 304-315. |
/
| 〈 |
|
〉 |